> ## Content Index
> Fetch the complete content index at: https://www.tidemetrix.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Divi's expands peptide synthesis with new 3,000-litre lines
- URL: https://www.tidemetrix.com/divis-expands-peptide-synthesis-with-new-3-000-litre-lines/
- Published: 2026-11-13T10:39:00.000Z
- Updated: 2026-11-14T10:40:57.000Z
- Description: Divi's is adding large-scale peptide synthesis equipment while manufacturing its own resins and protected amino acids, highlighting how integrated raw-material supply is becoming part of the competition for peptide manufacturing contracts.
- Author: TideMetrix Editorial
- Tags: Capacity, India, Divi's Laboratories, #brief

Divi's Laboratories is installing additional 3,000-litre solid-phase peptide synthesis (SPPS) lines to support growing customer programmes, according to its November 7 earnings call, whose transcript was filed on November 13.

The expansion builds on previously disclosed equipment investments, with additional lines being introduced as customer requirements develop. Divi's did not disclose how many lines are being added, their commissioning schedule or the company's total peptide synthesis capacity.

The Indian manufacturer described a peptide production platform spanning building blocks, dipeptides, tripeptides and larger peptide fragments. Several products are undergoing validation or customer qualification, with the company focusing on innovator programmes rather than generic peptides.

Divi's also manufactures its own synthesis resins, protected amino acids and TAGs, giving it greater control over key inputs used in peptide production. The company did not indicate whether these materials are available for sale to outside manufacturers.

The company is also developing its peptide purification capabilities. Management described gram-scale purification work at its peptide centre of excellence and indicated that further investment could follow as customer programmes advance toward commercialization.

The additional 3,000-litre lines represent synthesis equipment capacity rather than annual peptide output. Divi's has not disclosed its total peptide production capacity or a peptide-specific investment figure.

### Sources

- [Divi's Laboratories — November 13 filing, transcript of November 7 earnings call](https://nsearchives.nseindia.com/corporate/DIVISLAB%5F13112026113547%5FTranscript%5FQ2FY27%5FEarnings%5FCall%5F0711026.pdf?ref=tidemetrix.com)